Idorsia Ltd (IDIA.SW) on Wednesday announced a new analysis from the Phase 3 PRECISION study has been released, showing that aprocitentan can significantly lower blood pressure and reduce albuminuria in patients dealing with chronic kidney disease and confirmed resistant hypertension.
The treatment, which is already on the market as TRYVIO/JERAYGO, was generally well tolerated and didn't raise the risk of hyperkalemia. Clinicians pointed out its impressive antiproteinuric effect showing reductions of up to 60 percent along with notable and sustained improvements in blood pressure.
Idorsia believes these results highlight aprocitentan as an option for patients who have few choices and face high cardiovascular and kidney risks.
IDIA.SW is currently trading at CHF 4.1450 up CHF 0.30 or 7.8023 percent on the SIX Swiss Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.